ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Glycine Is Graft Protective and Improves Kidney Function After Liver Transplantation: Data from HEGPOL-Trial.

A. Nickkholgh,1 P. Schemmer,1 G. Polychronidis,1 S. Luntz,2 E. Mayatepek,3 M. Büchler,1 E. Klar.4

1General, Abdominal and Transplant Surgery, Ruprecht-Karls University, Heidelberg, BW, Germany
2Coordination Center for Clinical Trials (KKS), Heidelberg, BW, Germany
3Department of General Pediatrics, Heinrich-Heine-University, Düsseldorf, RP, Germany
4Department of Surgery, University of Rostock, Rostock, Germany.

Meeting: 2016 American Transplant Congress

Abstract number: 500

Keywords: Liver transplantation

Session Information

Date: Tuesday, June 14, 2016

Session Name: Concurrent Session: Ischemia Reperfusion Injury: Clinical Innovation

Session Time: 4:30pm-6:00pm

 Presentation Time: 5:18pm-5:30pm

Location: Room 311

Related Abstracts
  • Tacrolimus Concentration Variability Is Associated with Delayed Graft Function and Diminished Renal Function in Kidney Transplant Recipients
  • Adoptive Immunotherapy With Liver Allograft-Derived NK Cells Improves Recurrence-Free Survival After Living-Donor Liver Transplantation in Patients With Hepatocellular Carcinoma

Introduction: In experimental liver transplantation (LTx), glycine, a non-essential amino acid, has been shown to prevent the activation of Kupffer cells and to reduce ischemia/reperfusion injury (IRI) in the liver. Material and Methods: A randomized controlled double-blinded clinical trial with two parallel study arms was performed. A total of 130 patients undergoing primary whole-liver transplantation were randomized and received 250 ml of either 4.4 % glycine solution (n=66) or injectable water (n=64) intravenously (i.v.) during the anhepatic phase and once a day during the first 7 consecutive postoperative days. Primary endpoints were peak levels of aspartate-amino-transaminase (AST)/alanine-aminotransaminase (ALT) as surrogates for the progression of liver related IRI, as well as graft and patient survival. Furthermore, the effect of glycine on cyclosporine A-induced nephrotoxicity is evaluated. Results: The intention to treat analysis as well as the per protocol analysis showed no difference in primary or secondary endpoints between the two study arms. A post-hoc subgroup analysis comparing patients with very high plasma glycine concentrations during the anhepatic phase of LTx (≥7000 ng/ml, n=29) and those with lower concentrations (<7000 ng/ml; n=68) was performed. A relative but not statistically significant reduction of ALT levels during the first 24 hrs and on the first day after LTx, as well as an improvement of patients' overall survival was related with higher plasma glycine levels. Comparison of the post-reperfusion biopsy results showed a significant reduction in both mild and moderate IRI in patients with very high plasma glycine concentrations. Glycine improved eGFR, not only in patients within the target Cyclosporine trough levels, but also in patients with trough levels much higher than target. Conclusion: Although the per protocol analysis could not verify the hypothesized effects of glycine, very high plasma concentrations of glycine achieved at the anhepatic phase proved to be safe, hepatoprotective and nephroprotective.

CITATION INFORMATION: Nickkholgh A, Schemmer P, Polychronidis G, Luntz S, Mayatepek E, Büchler M, Klar E. Glycine Is Graft Protective and Improves Kidney Function After Liver Transplantation: Data from HEGPOL-Trial. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Nickkholgh A, Schemmer P, Polychronidis G, Luntz S, Mayatepek E, Büchler M, Klar E. Glycine Is Graft Protective and Improves Kidney Function After Liver Transplantation: Data from HEGPOL-Trial. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/glycine-is-graft-protective-and-improves-kidney-function-after-liver-transplantation-data-from-hegpol-trial/. Accessed March 6, 2021.

« Back to 2016 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Home
  • Search
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.